TT 01025
Alternative Names: LG-00303174; LG303174; LR-20056; TT-01025; TT-01025-CLLatest Information Update: 28 Sep 2024
At a glance
- Originator TransThera Biosciences
- Developer LG Chem; TransThera Biosciences
- Class Anti-inflammatories; Hepatoprotectants; Small molecules
- Mechanism of Action AOC3 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-alcoholic steatohepatitis
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in China (PO, Tablet)
- 28 Mar 2024 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis(In volunteers) in USA (PO, Tablet)
- 27 Apr 2022 LG Chem completes enrolment in its phase I trial for Non-alcoholic steatohepatitis (In volunteers) in USA (PO) (NCT04730050)